Premium
Statin or ACE Inhibitor Improve Vascular Dysfunction in Zucker Obese and ZDF Rats
Author(s) -
Oltman Christine L.,
Kleinschmidt Travis L.,
Yorek Mark A.
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1196-d
Subject(s) - medicine , rosuvastatin , endocrinology , endothelial dysfunction , enalapril , atorvastatin , statin , mesenteric arteries , diabetes mellitus , ace inhibitor , angiotensin converting enzyme , blood pressure , artery
Previous studies have shown vascular dysfunction in small coronary and mesenteric arteries from Zucker obese and Zucker Diabetic Fatty (ZDF) rats. Our hypothesis is that treatment with HMG‐CoA reductase inhibitor (statin) or angiotension converting enzyme inhibitor (ACEi) will improve vascular dysfunction in these rat models. Zucker obese and ZDF rats were treated with Rosuvastatin (50mg/Kg/day) or Enalapril (40mg/Kg/day) for 12 weeks. We examined small ventricular and mesenteric vessels using an isolated vessel preparation. Acetylcholine (Ach, 10‐10–10‐4 M) dilation was evaluated after U46619 constriction. Results: % Relaxation to 10 ?M Ach, (n).Ach responses were attenuated in both vascular beds from Zucker obese and ZDF rats compared to vessels from lean rats. Ach responses were augmented in vessels from statin or ACEi treated rats, compared to vessels from untreated rats. Endothelial dysfunction was improved when Zucker, and to a lesser degree when ZDF rats were treated with statin or ACEi suggesting more aggressive therapy is needed when hyperglycemia is involved. Supported by VA Merits to Drs. Oltman and Yorek.